These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38825519)

  • 1. [Current state of graft-versus-host disease prophylaxis with PTCy for allogeneic hematopoietic stem cell transplantation].
    Nakamae H
    Rinsho Ketsueki; 2024; 65(5):391-400. PubMed ID: 38825519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.
    Nakamae H
    Front Immunol; 2024; 15():1403936. PubMed ID: 38903503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
    Nunes NS; Kanakry CG
    Front Immunol; 2019; 10():2668. PubMed ID: 31849930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
    Nakamae H
    Int J Hematol; 2022 Oct; 116(4):465-481. PubMed ID: 35930118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.
    Oshrine B; Innamarato P; Branthoover H; Nagle L; Verdugo P; Pilon-Thomas S; Beatty M
    Transplant Cell Ther; 2022 Apr; 28(4):203.e1-203.e7. PubMed ID: 34995816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
    Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
    Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
    Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
    Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
    Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
    Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
    Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
    Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
    Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
    Front Immunol; 2022; 13():796349. PubMed ID: 35242129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New era of GVHD prophylaxis using posttransplant cyclophosphamide].
    Sugita J
    Rinsho Ketsueki; 2024; 65(4):272-281. PubMed ID: 38684438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.